Review Article
Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
Table 5
Patient characteristics and treatment outcomes.
| | | | RT-group | CCRT-group | -value |
| | Patient characteristics | Number of patients | | 21 | 20 | | | Median age | | 67 | 59 | | | Histology | SCC | 21 | 20 | | | Others | 0 | 0 | | | Dose of nedaplatin administered, mg/m2 | Median (range) | — | 35 (10–45) | | | Courses of nedaplatin administered | Median (range) | — | 5 (2–5) | |
| | Treatment outcome | PFS, months | Median (range) | 7 (0–60) | 60 (0–60) | .0015 | | Mean | 21.4 | 43.3 | | | OS, months | Median | 29 (1–60) | 60 (5–60) | .0364 | | Mean | 32.3 | 47 | | | Duration of radiotherapy | Median (range) | 47 (41-61) | 45 (40–57) | NS | | Patients with recurrence (%) | | 14 (66.7%) | 7 (35%) | NS | | Patients with grade 3-4 acute toxicity (%) | | 1 (4.8%) | 10 (50%) | .0014 | | Patients with grade 3-4 late toxicity (%) | | 0 (0%) | 2 (10%) | NS |
|
|
PFS: progression-free survival, OS: overall survival, SCC: squamous cell carcinoma, CCR: concurrent chemoradiotherapy, RT: radiotherapy.
|
